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Chapter 1 – Introduction 
Background and Significance 
  Cardiovascular disease (CVD) is the leading cause of death in the United States (US) 
being responsible for more than 800,000 (32.8%) deaths annually [1, 2]. Hypertension [systolic 
blood pressure (SBP) >140 mmHg and/or >90 mmHg diastolic (DBP)] is strongly associated 
with all cause and CVD mortality [3]. Approximately, 32.6% of US adults ≥20 yr have 
hypertension and 17.2% of US adults ≥20 yr are unaware of their elevated blood pressure (BP) 
[2]. One in four people with prehypertension (120 - 139 mmHg SBP and/or 80 - 89 mmHg DBP) 
will develop hypertension within 4 yr [4]. Pre-hypertension in individuals >60 yr is associated 
with a 1.5 to 2-fold risk of experiencing a major CVD event [2]. Individuals with normal BP 
(<120 mmHg SBP and <80 mmHg DBP) at 50 yr have a 90% risk of developing hypertension 
within their lifetime [4]. The estimated medical cost for treatment of hypertension is $46.4 
billion annually [2]. The economic impact of hypertension on the US health care system has 
made it a critical public health concern and led to a focus on the importance of prevention and 
improved management.  
 Accumulating evidence indicates insufficient levels of vitamin D (VitD) are associated 
with high BP [5-7]. The currently used and accepted classification scheme for serum VitD is 
displayed in Table 1. Martins et al. (2007) examined data from the third National Health and 
Nutritional Examination Survey (NHANES III) and found the prevalence of hypertension to be 
30% higher among US adults in the lowest quartile of serum VitD (21 ng/ml when compared to 
the highest quartile (37 ng/ml) adjusted for age, sex, race, and body mass index (BMI) [10]. 
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Table 1. Classification scheme of serum vitamin D [8, 9] 
Vitamin D / 
25(OH)D Status 
ng/ml nmol/l 
Sufficient ≥ 30 ≥ 75 
Insufficient 20 - 29 50 - 72 
Deficient ≤ 19 47 
Severe Deficiency ≤ 10 25 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ng/ml, nanograms per milliliter, 
nmol/l, nanomoles per liter 
 
Furthermore, Foreman et al. (2007) investigated the association between serum VitD 
levels and risk of incident hypertension among 613 men and 1,198 women (BP >140/90 mmHg) 
aged 40 –79 yr (92% Caucasian, 8% unspecified). They concluded the relative risk of developing 
hypertension over a period of 4 to 8 yr among those deficient in plasma VitD (<15 ng/ml) was 
6.13 in men and 2.67 in women [11]. This evidence suggests there is an association between 
lower levels of VitD and increased risk of hypertension; however, not all investigators reach 
these same conclusions [7, 10, 12-18]. 
Jorde et al. (2010) examined the cross-sectional relationship between levels of serum 
VitD and resting BP over 12 yr among 2,385 healthy men and women ≥25 yr who did not use BP 
medication (mean BP, 142/82 mmHg). After adjusting for sex, age, BMI and physical activity, 
the difference in SBP between the lowest and highest quartiles of serum VitD was not 
statistically significant. Jorde et al. concluded VitD status does not influence resting BP or 
predict future hypertension or elevated BP [13].  In 2003, Muray et al. examined the influence of 
VitD on resting BP among 590 healthy men and women and found SBP and DBP were higher in 
men with elevated levels of VitD, whereas there was no association between VitD levels and 
resting BP among women [14]. These findings suggest VitD may have a gender dependent effect 
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on BP. The existent literature on the association between VitD and resting BP is mixed and 
indicates a need for additional research [15-21]. 
Problem Statement 
  The evidence supporting an inverse relationship between VitD levels and risk of 
hypertension is controversial [19, 20]. Several studies have shown lower levels of serum VitD 
are associated with elevated resting BP [22-25]. However, other studies have shown no 
relationship between serum VitD and resting BP [13, 26-29]. Additionally, several studies have 
found higher levels of VitD are positively correlated with elevated resting BP [14, 30-32]. 
Further research is needed to resolve this controversy. The majority of cross-sectional studies 
examine individuals with insufficient and deficient levels of VitD. Thus, the purpose of this 
study will be to investigate the relationship between BP and individuals with VitD levels ≥34 
ng/ml and those with VitD levels <34 ng/ml. The median VitD level among the sample studied 
was 34ng/ml and therefore it was chosen as the cutoff value between groups. 
 To date, there are no published studies examining the relationship between VitD and the 
peak BP response to a graded exercise stress test (GEST). An exaggerated SBP response to peak 
exercise (210 mmHg in men and 190 mmHg in women) [33] is an independent risk factor for 
CVD and may predict future hypertension [33-36]. Miyai et al. [35], investigated the peak BP 
response to a GEST as a predictor of future hypertension among 726 men (42.98.5 yr) who 
completed a GEST. The participants did not use BP medication and had normal resting BP (SBP 
<120 mmHg and DBP <80mmHg). The average follow up was 4.7 yr after the initial visit. The 
cumulative incidence of hypertension increased progressively among individuals with higher 
percentiles of a peak SBP response to the GEST (relative risk 3.8). An exaggerated peak SBP 
response to a GEST was associated with a 3-to 4-fold greater risk of developing hypertension. 
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These results indicate that an exaggerated peak SBP response to a GEST is predictive of future 
hypertension [35, 37-39]. Further understanding of the relationship between VitD and the peak 
BP response to a GEST may be of clinical significance for the prevention, treatment, and control 
of hypertension [34, 35, 39]. 
  This proposed study will examine the relationship between VitD and resting BP and will 
attempt to provide further insight into reasons for the contrasting results in the literature. It will 
also examine the effect of VitD on the peak BP response to a GEST. A major strength of this 
study is that it examines VitD status in a large cohort of healthy men and women spanning an age 
range of 61 yr. (20 – 81 yr.) [40].  
Specific Aims  
 The aims of this study are to examine the relationship among serum VitD and resting BP 
and the peak SBP response to a GEST. 
 Specific Aim 1: To examine the influence of VitD on resting BP. 
 Hypothesis 1: Individuals with the lowest levels of VitD will manifest the highest  
resting BP.  
 Alternative Hypothesis: There will be no association between VitD levels and resting BP.  
 Specific Aim 2: To investigate the relationship between VitD and the peak SBP response 
to a GEST. 
 Hypothesis 2: Individuals with the lowest levels of VitD will manifest the highest peak 
SBP response to a GEST. 
 Alternative Hypothesis: There will be no association between VitD levels and the peak 
SBP response to a GEST. 
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Chapter 2 - Review of Literature 
Introduction 
Despite marketing claims from supplement manufactures such as Ortho Molecular 
Products that VitD can reduce BP and promote cardiovascular health, much is still unknown 
about the association between VitD and BP. A biologically plausible link between VitD and BP 
may be better understood through a greater comprehension of the mechanistic pathways in which 
VitD may affect the cardiovascular system. VitD is a unique nutrient that binds to receptor cells 
throughout the body and initiates hormonal responses that produce a myriad of feedback loops 
related to its health effects [41]. For example, the primary role of VitD and its active metabolites 
is to increase or maintain intestinal absorption of calcium and phosphate. If there is a disruption 
in the mineral levels within the blood stream due to either an excess of circulating VitD an 
increase in mineralization among vessel walls may occur [42]. Increased mineral deposits such 
as calcium on the vessel surface results in hardening and inflammation of the arterial walls [42]. 
Degradation of the arterial walls through the breakdown of elastin resulting from the buildup of 
calcium and phosphates compromises the structural integrity of the vessel. This mechanism 
reduces reactivity and elasticity within the vessel and ultimately increases BP [42]. VitD is 
believed to have a biphasic relationship with vascular calcification in both excess (>30ng/ml) 
and deficiency (<15ng/ml) [43]. In addition to vascular calcification many other mechanisms 
exist that influence the relationship between VitD and BP. The following review aims to 
investigate that relationship by providing a systematic analysis of the current body of literature 
and by examining the mechanistic links that have an influential role on both VitD and BP.  
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Literature Requirements 
The current body of literature investigating the relationship between VitD and BP is 
largely characterized by cross-sectional studies that have resulted in inconclusive findings. For 
the purpose of this review, studies examining the relationship between VitD and BP that do not 
report mean VitD levels for subjects have been excluded [22, 24, 44-46]. Furthermore, studies 
consisting of children or adolescents, individuals with kidney disease, metabolic syndrome, 
diabetes, pregnancy or currently hospitalized for unspecified reasons have also been excluded 
from this review [28, 30, 47-49]. Studies examining the relationship between VitD and BP 
through the use of an intervention such as oral or UVB supplementation have been explored. 
However, in an effort to focus primarily on studies similar to the cross-sectional design of 
STOMP, which did not consist of a VitD intervention, only a brief overview of the findings from 
these intervention studies have been examined for informative purposes only and their findings 
have been excluded from this review [23, 32, 50-55]. Based on the criteria stated above, there are 
currently 19 cross sectional studies examining the effects of VitD on resting BP in adults >18 yr 
(Appendix A). VitD was found to lower resting BP in nine of the cross-sectional studies [19, 25, 
56-62], while seven studies found no association between VitD and BP [13, 26, 27, 29, 63-65], 
and three studies found a positive relationship in which increased levels of VitD were associated 
with an increased resting BP [14, 31, 66].  
To date, two meta-analyses [67, 68] and two systematic reviews [9, 69] meeting the 
inclusion criteria for this review have been conducted examining the association between VitD 
and resting BP. Study quality for the systematic reviews and meta-analyses contained in this 
literature review have been critiqued by the author of this review using the Preferred Reporting 
Items for Systematic reviews & Meta-Analyses (PRISMA) checklist [70]. The PRISMA 
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checklist consists of 27-items and a four-phase flow-diagram to ensure the complete reporting of 
systematic reviews and meta-analyses [70]. The 27 checklist items pertain to the content of a 
review or analysis, which include the title, abstract, methods, results, discussion and funding 
[70]. The flow diagram depicts the flow of information through the different phases of a review 
and lists the number of studies identified, included and excluded, and the reasons for exclusion 
[70].  
In 2010, Burgaz et al. conducted a meta-analysis examining the blood concentration of 
VitD and its relationship with hypertension. Studies were included if they had a cohort, case-
control or cross-sectional design with a hypertension outcome. The analysis consisted of 18 
studies that meet the inclusion criteria. Participants included in the analysis were men and 
women between 18-96 yr. The concentration of serum or plasma 25(OH)D was the independent 
variable for the included studies and the outcome variable was hypertension [67]. Data extraction 
for the analysis was conducted independently by two investigators with the following relevant 
data being extracted from each study: sex, age, study design, method of measuring blood 
25(OH)D concentration, mean 25(OH)D level, BP risk classification, and risk estimates (RR, 
HR, OR). The quality of the studies included in the meta-analysis was in accordance with the 
nine-star Newcastle-Ottawa Scale [71], which found no evidence of publication bias on any of 
the encompassing studies [67].  
Of the 18 studies included in the analysis, Burgaz (2010) found the blood concentration 
of VitD was inversely associated with hypertension in 14 studies (odds ratio, 0.16-0.87). 
However, out of the 14 studies that found higher levels of VitD resulted in reduced BP, only 10 
of those studies showed a significant association between VitD and hypertension (P < 0.05). The 
remaining four studies in the analysis showed a non-significant positive association between 
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25(OH)D and hypertension, indicating higher VitD levels are associated with higher BP (odds 
ratio, 1.01-1.28). Heterogeneity was statistically significant among all studies (P=0.007, 
I2=32%). The pooled odds ratio of hypertension for the highest category of blood 25(OH)D 
concentration versus the lowest category was 0.73 (95% CI: 0.63 – 0.84). The findings from this 
meta-analysis indicate an inverse relationship between blood 25(OH)D concentration and 
hypertension [67].  
The meta-analysis conducted by Burgaz (2010) has many limitations, which indicate the 
need for further analyses. Few of the studies included in this meta-analysis were designed to 
specifically examine the effect of blood 25(OH)D concentrations on the risk of hypertension in a 
general population [11, 13, 25, 72]. Rather the primary aim for the majority of the studies 
included in this meta-analysis was determining the association between VitD and the metabolic 
syndrome. Therefore, it is conceivable that inadequate control of residual or unknown 
confounders may have implications in the observed findings. Furthermore, four studies [11, 60, 
73, 74] included in the analysis used self-reported hypertension as outcome, which can lead to a 
false estimate of average BP and may bias the results toward underestimation or exaggeration of 
the hypertension risk estimates.  
The findings of Burgaz, (2010) that suggested an inverse relationship between VitD and 
hypertension were refuted by two additional meta-analyses conducted by Witham et al. (2009) 
and Elamin et al. (2011). Witham et al. [20] examined eight randomized controlled trials (n = 
545) on the effect of VitD supplementation on BP among individuals with hypertension. The 
authors found weak evidence to support a small non-significant effect of VitD supplementation 
on BP among individuals with hypertension [20]. Similarly, Elamin et al. (2011) analyzed 14 
RCT’s examining the relationship between VitD and BP. The 14 studies consisted of an 
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intervention cohort of 751 subjects and a control of 767 subjects. Statistical significance was not 
achieved in either SBP (P= 0.95) or DBP (P=0.33), The reviewers concluded that the data 
available were unable to demonstrate an association between VitD and BP [75]. These meta-
analyses examined the effect of VitD supplementation on BP among a variety of cohorts 
including individuals with chronic kidney disease, Type 2 diabetes mellitus, the metabolic 
syndrome, and osteoporosis and have therefore been excluded from this review [20, 75].  
One of the many challenges when reviewing literature on the controversial topic of the 
association between VitD and BP is to discern the questionable studies with a less than desirable 
quality rating that repeatedly influence the results of meta-analyses and systematic reviews. For 
example, in 2010, Pittas et al. conducted a systematic review examining the association between 
VitD and cardiometabolic outcomes (Type 2 diabetes mellitus, hypertension, and CVD.) 
Although the systematic review consisted primarily of intervention studies, three longitudinal 
observational cohort studies with questionable methodology were also included in the systematic 
review. The three longitudinal studies conducted by Forman et al. (2007, 2008) and Wang et al. 
(2008) examined the association between VitD and hypertension using self-reported BP 
measurements to ascertain hypertension status [11, 73, 76]. Wang et al. (2008) examined the 
association between VitD and hypertension using both self-reported BP measurements and 
dietary intake as well as self-reported UVB exposure for VitD status. After an 8 yr follow up, 
Wang et al. (2008) found no association between VitD status and hypertension. However, 
Forman et al. (2007, 2008) who determined VitD status through measured 25(OH)D 
concentration found a significant association between lower 25(OH)D concentration and higher 
risk for incident hypertension after follow up at 7 and 8 yr  (RR, 1.76 [CI, 1.27 to 1.24]) [11, 73]. 
Furthermore, Forman excluded women with BMI >30 kg/m2 and only included young women 32 
  
 10 
to 52 yr which limits the generalizability of the results. The authors of the systematic review 
concluded that lower 25(OH)D concentration or VitD intake was associated with increased risk 
for incident hypertension, however not a single BP measurement was clinically obtained 
throughout the duration of all three studies. The findings from these three longitudinal studies 
demonstrate how questionable methodology can produce unconvincing results that impact the 
overall findings of the systematic review or meta-analysis. 
Soon after the systematic review conducted by Pittas et al. (2010) suggested an inverse 
relationship between VitD status and increased risk for hypertension, Jorde et al. (2010) 
challenged these findings in a cross sectional study examining whether VitD status predicts 
future hypertension. In 2010, Jorde et al. [13] measured serum 25(OH)D status in 4,125 subjects 
from Tromso, Norway who did not use BP medication (aged 50-74 yr). This measurement was 
repeated 14 years later among 2,385 of the original subjects. When adjusted for sex, age, BMI, 
and physical activity, the researchers found serum 25(OH)D obtained in 1994 was not correlated 
with increased BP or the development of hypertension in 2008 (DBP, r = -0.018; SBP, r = -
0.012) [13]. The findings of Jorde et al. (2010) that found no association between VitD and 
increased BP conflicts with much of the existing literature and indicates a need for additional 
research with exemplary methodology.  
These findings were recently supported by Li et al. (2012) who conducted a cross-
sectional study examining the association between VitD and BP among 1,428 Chinese adults 
(20-83 yr). Each participant’s BP was measured three times by a physician using an automatic 
BP monitor after the individual had been seated for 5 minutes. The average of the three readings 
was used for analysis. Serum 25(OH)D was obtained from each participant and determined by 
radioimmunoassay. Mean levels of VitD among the cohort were 23 ng/ml, which were classified 
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as insufficient. 25(OH)D was not associated with BP in both adjusted and unadjusted models for 
both men and women (P  0.10). Adjusted models were controlled for age, sex, BMI, alcohol 
intake, smoking, and family history of hypertension. The researchers concluded serum VitD is 
not independently associated with BP or risk of hypertension [63].  
It is important to note that a primary limitation of cross sectional studies examining the 
association between VitD and BP is that lower VitD status may reflect nonspecific or 
undiagnosed chronic illnesses which may result in reverse causality [67]. These illnesses include, 
cancer, multiple sclerosis, Type 1 diabetes mellitus, depression, seasonal affective disorder, 
rheumatoid arthritis, psoriasis, tuberculosis and inflammatory bowel disease [8, 77]. Both 
longitudinal and cross-sectional studies have shown mixed results. Longitudinal studies such as 
the large population-based Norwegian Tromso study [13] did not find an association between 
VitD and BP after 14 yr. However, the Michigan Bone Health and Metabolism study conducted 
by Griffin et al. (2010) found significantly lower DBP among 413 women with VitD deficiency 
when compared to women with adequate VitD after 14 yr[27]. There were no differences in SBP 
between groups. Another longitudinal study conducted by Margolis et al. (2012) found no 
association between VitD and BP among 4,863 women over 7 yr. Similarly, cross-sectional 
studies have produced mixed results as well. A population-based study by Parikh et al. (2012) 
found that vitamin D was inversely correlated with both SBP (p=0.02) and SBP (p<0.01) among 
701 individuals with a mean VitD level of 30 ng/mL, while Lihua et al. (2012) found no 
association between VitD and BP among 1420 individuals[63, 78].  
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Vitamin D and the Renin-Angiotensin-Aldosterone System 
 Numerous studies have suggested a correlation between VitD deficiency and activation 
of the renin-angiotensin-aldosterone system (RAAS) leading to increased BP. [79-84]. The 
RAAS is a regulatory cascade that plays a central role in maintaining BP and electrolyte 
homeostasis. The cascade of events triggered through stimulation of the RAAS that leads to the 
modulation of BP begins with the release of renin from the juxtaglomerular cells of the kidneys. 
The main purpose of renin is to cleave the amino acid angiotensinogen resulting in angiotensin I. 
Angiotensin I is further converted into angiotensin II (Ang II) by angiotensin-converting enzyme 
found primarily within the capillaries of the lung. Ang II is the key bioactive product of the 
RAAS acting as an endocrine, autocrine, and intracrine hormone and is responsible for 
vasoconstriction of the vessels resulting in an increase in BP [79-82]. Additional actions of Ang 
II include elevating sodium and water retention, which increases blood plasma volume and 
cardiac output, thus increasing BP [9]. Studies have shown that lower levels of biologically 
active forms of VitD such as 1,25(OH)2D and 25(OH)D are associated with increased plasma 
renin activity and higher Ang II concentrations [83, 85, 86]. 
The metabolism of VitD and the mechanistic pathways in which VitD may lower BP are 
depicted in figure 1. 
The primary mechanism linking VitD with an increase in BP is through suppression of 
renin within the juxtaglomerular cells [83, 84]. Li et al. [87] investigated the association between 
the VitD receptors (VDR) and renin and found that VDR knockout mice have a three-fold 
increase in renin expression and a 2.5 fold increase in plasma Ang II compared to a control 
group. Obstructing VitD synthesis in the VDR knockout mice led to an increase in renin 
expression that resulted into the development of hypertension and cardiac hypertrophy, whereas 
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the control group received regular treatment of VitD and their renin levels and BP decreased 
[87]. Similarly, Zhou et al. [88] examined the cardiovascular effect of VitD among 1alpha-
hydroxylase knockout mice. 1alpha-hydroxylase is an enzyme that catalyzes the hydroxylation of 
calcifediol to calcitriol, which is the bioactive form of VitD. The 1alpha-hydroxylase knockout 
mice that were unable to synthesize calcifediol into an active form of VitD displayed enhanced 
RAAS activity in addition to hypertension and cardiac hypertrophy. All the aforementioned 
effects were diminished with the administration of the biologically active form of VitD, 
1,25(OH)2D [88]. The collective work of both Li et al. and Zhou et al. has shown that the VDR 
acts to suppress renin gene expression and consequently modulate BP [87-89]. 
Among the several cross-sectional and prospective studies investigating the association of 
VitD deficiency and BP among humans, Forman et al [90] provided a mechanistic role of VitD 
in RAAS regulation. The researchers examined the relation between plasma VitD concentrations 
and both renin and Ang II levels among 184 individuals with normal BP. The individuals were 
placed on a high sodium diet for 3 to 7 days before the study because the range of renal plasma 
flow responsiveness in high sodium balance allows for more accurate detection of individual 
differences among participants. The researchers found that lower VitD levels (<15.0 ng/ml) 
correlated with higher levels of Ang II at baseline (P = 0.03). Plasma renin activity was also 
higher among individuals with insufficient levels of VitD, however not significantly (p = 0.40) 
[90]. These findings were confirmed in subsequent studies [83, 84] and indicate that VitD has an 
inverse association with both plasma renin and Ang II.  
The RAAS has long been recognized as an important regulator of BP and electrolyte 
balance. Recent findings suggest that VitD is a potent endocrine suppressor of renin, which 
regulates the RAAS. VitD deficiency has been found to stimulate renin expression, whereas 
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sufficient VitD levels have inhibited renin synthesis. The role of renin is a key component when 
examining the association between VitD and BP. This association may provide an important 
mechanistic explanation for epidemiological data supporting the relationship between VitD 
deficiency and elevated BP.  
 
              Figure 1. Vitamin D Metabolism and Mechanism of Action [9] 
 
 
Abbreviations: UVB, ultraviolet B; Ca, calcium; PO4, phosphate 
  
 15 
Vitamin D & Nitric Oxide  
Another proposed hypothesis for the inverse association between VitD and BP is that 
serum VitD improves blood flow by enhancing vascular reactivity and endothelial function 
through the production and release of nitric oxide synthase (NOS) [47]. NOS is the key nitric 
oxide synthesizing enzyme responsible for converting nitric oxide into the biologically active 
form responsible for vasodilation and regulating vascular smooth muscle tone and reactivity [91, 
92]. NOS opposes the vasoconstrictive properties of endothelin-1 and Ang II produced by the 
RAAS[91, 92]. The ability of VitD to enhance vascular reactivity and endothelial function, thus 
stimulating vasoactive substances such as NOS and suppressing the secretion of Ang II indicates 
the potential for VitD to have BP lowering effects [9].  
Andrukhova et al. examined the association between VDR knockout mice and cell 
signaling within the endothelium to further understand the mechanisms by which VitD regulates 
vascular tone and cardiac function. The genetically modified mice were characterized by having 
lower bioavailability of nitric oxide due to reduced expression of endothelial NOS. VDR 
knockout mice they were fed a diet enriched with calcium, phosphate and lactose to ensure 
calcium homeostasis. After 12 months without cell signaling the mice had elevated BP, arterial 
stiffness, increased resistance of aortic blood flow, and structural remodeling of the aorta [93]. 
The authors found that reduced NOS production resulted in altered collagen and elastin content 
in the aorta by long term increases in mechanical strain [93]. Additionally, the authors found that 
VitD was a direct transcriptional regulator of endothelial NOS and that loss of VDR signaling 
increases arterial stiffness independent of activation of the RAAS. These findings indicate the 
importance of VDR signaling for maintaining efficient vascular function and may have important 
clinical implications in the treatment of CVD. 
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Vitamin D & Endothelial Dysfunction 
 Recent data indicate that low levels of VitD are associated with certain biomarkers 
related to endothelial dysfunction [94-96]. Endothelial dysfunction is observed through methods 
such as pulse wave velocity and carotid ultrasonography to determine if an increase in arterial 
wall thickness and stiffness has occured[94]. Endothelial dysfunction is characterized by an 
increase of adhesion molecule expression, which can result in systemic vascular inflammation, 
decreased myocyte contractility and increased insulin resistance [94-96]. The primary biomarker 
that is indicative of platelet function and inflammation is C-reactive protein [94, 97, 98]. C-
reactive protein is associated with inflammation and myofibroblast migration inside the vessel, 
which play an important role in the development of atherosclerosis. C-reactive protein is a 
crucial independent predictor of myocardial infarction, stroke, and vascular death [98]. 
 Sypniewska et al. (2013) examined the association between VitD status and biomarkers 
of endothelial dysfunction in adults with hypertension. They included 158 individuals aged 35-
65 yr with untreated or undiagnosed hypertension. No evidence of CVD or kidney disease was 
apparent in any of the individuals at the start of the study. Fasting venous blood was collected 
from the participants to determine VitD level. Echocardiography was measured to determine left 
ventricular mass and carotid ultrasonography was performed to assess carotid intima-media 
thickness, which is a measurement of atherosclerotic development. Additionally, carotid-femoral 
pulse wave velocity was measured as a measure of arterial stiffness and endothelial dysfunction. 
They found that individuals with VitD levels <20ng/ml had higher SBP than those with VitD 
>20ng/ml (p=0.03). C-reactive protein, was also higher among individuals with VitD <20ng/ml 
when compared to those with VitD >20ng/ml (p=0.001). Carotid intima-media thickness among 
individuals with VitD <20ng/ml was 0.81 ± 0.25 mm compared to 0.66 ± 0.15 in those with VitD 
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>20ng/ml (p=0.001). Pulse wave velocity was higher among those with VitD <20ng/ml (11.0 ± 
2.0 m/s) compared to those with VitD levels >20ng/ml (8.5 ± 1.6 m/s) (p=0.001). These findings 
indicate that individuals with VitD levels <20 ng/ml may be more likely to develop a higher 
amount of biomarkers that promote endothelial dysfunction resulting in compromised vascular 
reactivity. Compromised vascular reactivity is directly correlated to an increase in BP [17, 21, 
94, 98]. 
Vitamin D & Insulin Sensitivity  
 The endothelium regulates vascular tone by secreting vasodilators such as nitric oxide 
and vasoconstrictors such as endothelin [99]. However, individuals who are insulin resistant have 
an increase in the cytokine tumor necrosis factor alpha (TNF-a), which down regulates 
endothelial nitric oxide synthase and in-turn reduces production of the vasodilating nitric oxide 
[99]. This reduction of nitric oxide is directly association with an increase in BP [100]. Low 
levels of VitD are associated with hypertension and CVD and approximately half of all 
individuals with hypertension are insulin resistant [11, 22, 67, 101, 102]. Therefore, the 
associations between metabolic biomarkers such as fasting plasma insulin (FPI) and steady-state 
plasma glucose (SSPG) and BP have become a primary focus. 
Abbasi et al. (2014) examined 140 individuals with hypertension to determine if there 
was a relationship between VitD levels, insulin resistance, and CVD risk factors. The sample 
consisted of mostly obese (58%) and overweight (34%) men and women with a mean age 55 yr. 
Of the total sample, 79% were being treated with medication for hypertension. After an 
overnight fast, FPI and SSPG were collected via catheter. The researchers found significant 
inverse correlations between VitD levels and FPI (p=0.03) and SSPG (p=0.02). These 
correlations remained significant after adjusting for smoking status and the use of 
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antihypertensive medication. Additionally, the researchers found that individuals with 
insufficient levels of VitD (>20.3 ng/ml ±1.4) had SSPG levels >229 mg/dl and FPI levels of 
19.2 μU/ml classifying them as insulin resistant [17]. Insulin resistance as determined by SSPG 
levels showed a significant positive correlation among this sample to several CVD risk factors 
such as BMI (p<0.001), hypertension (p<0.001), heart rate (p=0.008), FPI (p<0.001), 
triglycerides (p<0.001), high-density lipoprotein cholesterol (p<0.001), and low-density 
lipoprotein cholesterol (p<0.001). SBP and DBP were not significantly associated with SSPG 
levels (p>0.05). However, insulin resistance is an independent predictor of hypertension. The 
findings of this study suggest that individuals with lower levels of VitD are more likely to have 
elevated SSPG and FPI levels classifying them as insulin resistant, which is significantly 
correlated to several other CVD risk factors including hypertension [17]. Insulin resistance is 
known to disturb nitric oxide mediated vasodilation and endothelial functions through the 
increase of TNF-a, which can result in vascular damage and lead to increased risk for long-term 
CVD.  
Vitamin D & Intervention Therapy 
 Much of the existing literature suggests that VitD deficiency may promote elevated BP 
and other cardiovascular complications [2, 15, 17, 21, 97, 103] suggesting the possibility that 
VitD supplementation could be a viable means of reducing BP. However, data from randomized 
control trials are limited and inconsistent [23, 32, 50-55]. In 2009, Witham et al. conducted a 
meta-analysis to determine whether VitD supplementation reduces BP. The analysis included 
eight randomized controlled trials (RCT) (n = 545) examining the effect of VitD 
supplementation on BP among individuals with hypertension (mean BP 148/87 mmHg, mean 
age 62.2 yr). All studies were independently reviewed by two researchers according to a 
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predetermined protocol and found significant heterogeneity between studies ((I2=62%, P=0.01). 
The studies showed a non-significant reduction in SBP among individuals with hypertension in 
the VitD group when compared with placebo (-3.6 mmHg SBP, P = 0.1) and a small yet 
statistically significant reduction in DBP (-3.1 mmHg DBP, P = 0.01). These findings indicate 
that VitD therapy is not an effective or beneficial way of reducing SBP among hypertensive 
individuals. The findings of Witham et al. were further supported by a meta-analysis conducted 
by Elamin et al. (2011). 
 In 2011, Elamin et al. analyzed 51 RCT with the primary aim of examining the 
relationship between VitD and cardiovascular outcomes (death, stroke, myocardial infarction). 
Secondarily, they examined the effect of VitD D on CVD risk factors (i.e., BP, glucose and 
lipids). Reviewers worked both independently and in pairs to extract study characteristics and 
outcomes of interest in all eligible trials of moderate quality (=0.80). Of the 51 RCT, 14 studies 
examined the effect of Vit D on BP. The 14 studies consisted of an intervention cohort of 751 
subjects and a control of 767 subjects. Subjects were predominantly unhealthy, older men and 
women 60 yr at risk of mortality (RR, 0.96), stroke (RR, 1.04), and myocardial infarction (RR, 
0.96). The reviewers concluded that the data available were unable to demonstrate an association 
between VitD and SBP (P= 0.95) or DBP (P=0.33), however heterogeneity was significant 
(I2=61%). [75]. 
 More recently in 2014, Arora et al. conducted a double-blind RCT to determine if VitD 
supplementation could be a viable intervention to reduce BP. The multicenter study examined 
383 individuals aged 18 to 50 yr (mean age, 36 ± 10 yr.) with VitD levels ≤ 25 ng/ml (median 
VitD, 15.3 ng/ml) and a SBP between 120-159 mmHg. Participants were randomized to high-
dose (4,000 IU/day) versus low-dose (400 IU/day) oral VitD supplementation for 6 months. 
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Follow-up visits occurred every 2 months until the end of the study and each visit consisted of 4 
BP measurements. Upon conclusion of the study the researchers found no significant difference 
in the mean 24-hour SBP between either the high dose group (-0.8 mmHg) or the low dose group 
(-1.6 mmHg) (p=0.71) [55]. The findings of Arora et al. (2014) are supported by two additional 
studies [104, 105].  
Larsen et al. (2012) examined 112 individuals with hypertension (mean age 61 ± 10 yr) 
who were randomized to 3,000 IU/day of VitD supplementation or a placebo for 5 months. The 
researchers found a nonsignificant reduction in 24 hour ambulatory BP among the intervention 
group (-3 mmHg, p=0.26) compared to the placebo group (-1mmHg, p=0.18). The findings of 
Larsen et al. were supported by a follow up study by Witham et al. (2013) examining the change 
in BP, arterial stiffness, and endothelial function after 1 year of VitD supplementation among 
159 elderly individuals (mean age 77 yr) [104]. The groups were given 100,000 IU of oral VitD 
or placebo every 3 months for 1 year. VitD levels increased 10 ng/ml among the intervention 
group at 6 months and plateaued for the remainder of the year compared to placebo (p<0.001). 
Although, VitD levels increased among the intervention group there was no significant effect on 
BP at 1 year (SBP, p=0.58; DBP, p=0.06). The results from intervention studies that aim to 
determine if VitD has clinical significance as a potential therapy among individuals combating 
elevated BP have been largely unsuccessful. Currently the tolerable upper intake level for VitD 
for ages 9-71 yr is 4,000 IU/day, however a review by Holick et al. found VitD toxicity to occur 
over several months with a daily dosage of 50,000 IU [8, 106]. With a range of 45,000 IU/day 
between current tolerable upper intake and documented VitD toxicity future intervention studies 
need to be conducted with an emphasis on dosage because it is entirely plausible that 4,000 
IU/day is not a dosage that will warrant a cardiovascular effect. 
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Vitamin D and Peak Blood Pressure  
BP changes in response to a graded exercise stress test (GEST) have been found to 
correspond to BP changes initiated by daily physical stress conditions and are therefore a 
valuable predictor of future hypertension [107, 108]. Considerable increases in BP during 
exercise have been found to increase risk of left ventricular hypertrophy, myocardial infarction, 
cerebrovascular stroke, and cardiovascular death [107-111].  
In 2007, Gupta et al. investigated whether the SBP response to a GEST is predictive of 
cardiovascular mortality among 6,145 individuals. Participants were grouped according to their 
exercise-induced increases in SBP (Group A, ≤43 mmHg, n = 3,062) (Group B, ≥ 44 mmHg, n = 
3,083). BP was measured manually before, during and after the GEST. All participants 
underwent the GEST with a mean follow up of 6.6 ± 3.7 yr. Multivariate analysis was used to 
adjust for baseline differences between the two groups. During the follow-up, 676 individuals 
died of cardiovascular causes with an annual cardiovascular mortality of 1.6%. Cardiovascular 
mortality was significantly higher in group A (13.7%) than in Group B (8.2%) (p <0.001). After 
adjusting for baseline differences in the two groups using multivariate analysis, an increase in 
SBP of <44 mmHg was a significant predictor of mortality (p <0.05). An increase in SBP ≥ 44 
mmHg from baseline was associated with better survival over long-term follow up even in 
patients with a history of hypertension. This study demonstrates that an increase in SBP with 
GEST predicts cardiovascular mortality independent of age and exercise capacity. These results 
were further supported by the work of Farah et al. in 2008.  
Farah et al. (2008) examined whether an exaggerated BP response to a GEST was 
predictive of future hypertension among 30 individuals with normal baseline BP (<140/90 
mmHg). The subjects performed a maximal GEST on a treadmill following the Bruce protocol 
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and were then divided into two groups. Group one consisted of 13 individuals who displayed 
exaggerated BP during the GEST (SBP  210 mmHg, DBP 105 mmHg) and group two 
consisted of 17 individuals who maintained a normal BP response to maximal exercise (SBP ≤ 
210 mmHg, DBP ≤105 mmHg). More individuals in group one developed hypertension than 
those in group two (P< 0.01) at the 2 yr follow up (10 vs 1, p <0.001). Of the participants that 
displayed an exaggerated BP during the GEST, 84% of them had developed hypertension by the 
2 yr follow up [112].  
The results of Farah et al. (2008) and Gupta et al. (2007) are consistent with those of 
Miyai et al. [35], who investigated the peak BP response to a GEST as a predictor of future 
hypertension among 726 men (42.98.5 yr). The participants who were not taking any BP 
medication and had normal resting BP (SBP <120 mmHg and DBP <80mmHg) were followed 
for a hypertensive outcome for 4.7 yr. The cumulative incidence of hypertension increased 
progressively among individuals with higher percentiles of a peak SBP response to the GEST 
(relative risk 3.8). An exaggerated peak SBP response to a GEST was associated with a 3-to 4-
fold greater risk of developing hypertension. Progression of hypertension was found in 114 
individuals (15.4%). These results indicated that an exaggerated peak SBP response to a GEST is 
predictive of future hypertension [35, 37-39].  
However, these findings were challenged when Manolio et al. [33] examined the 5 year 
risk of developing hypertension among individuals who displayed an exaggerated BP response to 
peak exercise. In a population-based study 687 men and women (18-30 yr) with normal resting 
BP displayed an exaggerated BP response to a maximal GEST (SBP > 210 mmHg in men, SBP 
190 > mmHg in women). The individuals who displayed an exaggerated BP response to peak 
exercise had increased their resting SBP an average of 5 mmHg and DBP 1 mmHg (p < 0.005) at 
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the 5 year follow up. Furthermore, they were 1.7 times more likely to develop hypertension when 
compared to those who displayed normal BP responses (p <0.001). However, after multivariate 
regression analysis was conducted there was no longer a significant association between 
exaggerated BP response to a GEST and a 5 yr risk of developing hypertension [33].  
The studies by Farah et al., Gupta et al. and Miyai et al. found that relative risk of 
hypertension and cardiovascular mortality among individuals with normal BP was greatly 
increased if they exhibited an exaggerated BP response to exercise. These findings indicate the 
importance of early detection through a GEST to reduce the risk of developing future 
hypertension. Among the current literature examining the association between VitD and BP none 
have yet to examine the relationship between VitD and the peak BP response to a graded 
exercise stress test (GEST). 
Conclusion 
VitD is a unique nutrient that binds to receptor cells throughout the body and initiates 
hormonal responses that produce a myriad of feedback loops related to its health effects. VitD 
can be viewed as the catalyst in many chain reactions that initiate several effects on the 
cardiovascular system. Much of the cross-sectional data suggest a strong association between 
VitD and BP, which is supported by several biologic pathways such as the release of nitric oxide 
from endothelial cells and the suppression of renin. However, longitudinal and RCTs have 
produced mixed or weak findings suggesting a relationship between VitD and BP. Several of 
these studies evaluate BP as a secondary outcome and use self-reported BP measurements. 
Additionally, most intervention studies used a low-dosage of VitD or included individuals with 
well-controlled hypertension. Findings that suggest VitD is effective for lowering or normalizing 
BP have been largely inconsistent and contradictory. Therefore, it is premature to conclude that 
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maintaining optimal VitD levels will provide beneficial results when trying to reduce or 
normalize BP. 
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Chapter 3 - Methods 
 This proposed sub-study investigated the effects of VitD on BP at rest and in response to 
a GEST using data from a larger study entitled, “The Effects of Statins on Muscle Performance” 
(STOMP). This sub-study used the methods  
and data only from STOMP prior to 
randomization. STOMP was funded by the 
National Institute of Health (NIH) 
(1R01HL081893-01A2) and conducted by 
researchers at Hartford Hospital, the 
University of Massachusetts, Amherst, and the 
University of Connecticut, Storrs. The 
institutional review boards at the three study 
sites approved the experimental design of 
STOMP which has been described in detail 
elsewhere (Figure 1) [40, 113]. STOMP was a 
double blind, placebo-controlled randomized 
trial designed to examine the association 
between atorvastatin (Lipitor) and the 
incidence of statin-induced muscle myopathy 
among 440 healthy men and women >20 yr 
over a 6 month period. Secondly, STOMP 
investigators examined the effects of statin on 
    Figure 1. Overview of STOMP study. 
TSH, thyroid stimulating hormone; ALT, alanine aminotransferase; 
CK, creatine kinase; CKMB, creatine kinase myocardial band 
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skeletal muscle strength,  
endurance and aerobic exercise performance. 
 
Subjects   
Subjects for the larger STOMP study were recruited through study flyers, email announcements, 
and radio/newspaper advertisements. STOMP volunteers included 216 women and 203 men with 
a mean age of 44.1 ± 16.1 yr. Subjects signed an informed consent approved by the Institution 
Review Boards at each of the testing sites.  
 Exclusionary criteria were individuals who had: (a) diabetes mellitus; (b) hyper- or 
hypothyroidism; (c) any kind of surgery or injury to the knees or hips that would prevent the 
individual from exercising vigorously on a treadmill; (d) history of or current treatment with 
cholesterol-lowering medications; (e) a heart condition that required medication or a restriction 
of activity (e.g., cardiac disease and peripheral vascular disease); or (f) anyone with hepatic 
disease (alanine aminotransferase > 2x the normal limit) or renal disease (creatinine > 2mg/L) as 
determined by the blood sample obtained during visit 1 (V1). Additionally, individuals that 
experienced occult cardiac ischemia during the physician-supervised treadmill test in V1 were 
excluded from the study [40, 113]. Individuals using antihypertensive medications were included 
as long as their BP was controlled (140/90 mmHg), and they had been on the antihypertensive 
medication for at least 3 months.  
Study Overview 
 STOMP consisted of six visits to the laboratory over a period of approximately 6 months, 
however; only the visits that pertain to this study will be discussed in the overview. During visit 
1 subjects provided an initial blood sample after fasting for 12 hours. The season in which the 
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blood samples were collected was recorded to account for potential seasonal variation of VitD 
levels. Total body VitD status was determined by measuring serum 25(OH)D, which is a 
measurement of the combined total of vitamin D2 and D3 levels in blood serum. Subjects then 
underwent a brief physical examination that included anthropometric and resting BP 
measurements as well as a physician supervised maximal GEST using a Bruce protocol with 
electrocardiographic monitoring. Study visit 2 occurred a minimum of 72 hr after visit 1 and 
included a maximal GEST using the modified Balke protocol to measure cardiorespiratory 
fitness. Approximately 90 days after visit 2 subjects provided another blood sample in a non-
fasted state. After another 90 days subjects provided a final blood sample after fasting for 12 hr 
and then conducted a maximal GEST using the modified Balke protocol to measure CRF [40, 
113, 114].  
Body Composition 
 During visit 1 the subject’s height and weight were measured and recorded to calculate 
BMI (kg/m2). Height was measured using a wall-mounted tape measure while the subject stood 
erect with his or her head in the neutral position. Weight was measured using a calibrated 
balance beam scale. Prior to measuring height and weight, subjects were instructed to remove 
their shoes and any heavy or bulky clothing, such as a jacket or sweatshirt.  
Blood Analyses 
 During visit 1 blood was collected from an antecubital vein without stasis by 
venipuncture. The blood samples sat at room temperature for a minimum of 10 minutes before 
being centrifuged at 3400 rpm for 15 minutes (VanGuard V6500, Hamilton Bell Co., Inc., 
Montvale, NJ, USA). After the blood samples were centrifuged, 1 mL aliquots of serum were 
obtained and shipped to Clinical Laboratory Partners in Hartford, CT where serum 25(OH)D 
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levels were obtained. This measurement was determined using a standard enzyme-linked 
immunosorbent assay protocol (ELISA) (Clinical Laboratory Partners, Newington, Connecticut).  
The ELISA protocol was used to determine 25(OH)D status by affixing an unspecified amount 
of 25(OH)D to a surface and then applying an anti-25(OH)D antibody over the surface. After an 
overnight incubation period the 25(OH)D antibody coupled to the enzyme. The chemical 
tetramethylbenzidine, which contains the enzyme's substrate was then added. The subsequent 
reaction produces a color change in the substrate which was used to determine serum 25(OH)D 
status [115]. A Clinical Laboratory Partners quality management team actively monitored 
performance indicators during specimen collection, analysis and reporting. The intra- and inter-
assay coefficients of variation for this analysis were 5.3% and 4.6% respectively. 
Peak Cardiopulmonary Graded Exercise Stress Test 
 During visit 2, CRF was measured with a peak GEST on a treadmill using a modified 
Balke protocol [40, 113, 114]. Prior to the GEST the subjects sat quietly for 5 minutes to allow 
for breath-by-breath analysis of expired gases (C02, 02 and VE) via an open circuit respiratory 
apparatus (ParvomedicsTrueOne 2400 metabolic cart, Parvomedics Corp, Sandy, UT, USA). 
After the 5 minutes of seated rest the subjects began the protocol by walking on the treadmill for 
2 minutes at a speed of 2 miles per hour and a 0% treadmill incline. After the initial 2 minutes, 
the speed of the treadmill was increased until the subject was running at a speed at which they 
could comfortably maintain a steady state for at least 30 minutes. Treadmill speed was kept 
constant throughout the remainder of the test, however, after every minute the incline of the 
treadmill was increased 1%. VO2 peak was determined directly during peak exercise. Heart rate 
(HR), BP and the individual’s rate of perceived exertion (RPE) [116] was recorded every third 
minute of the GEST [113]. HR was recorded using a Polar® HR monitor (Polar Electro®, 
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Kempele, Finland). RPE was recorded on a 6 to 20 point Borg scale. Criteria for GEST 
termination were: (a) an overall RPE  17; (b) a plateau in oxygen uptake; (c) a respiratory 
exchange ratio >1.1 ;(d) achievement of the age predicted maximum HR; and/or (e) termination 
by the subject due to fatigue or discomfort [113]. Monitoring of vital signs, RPE and expired gas 
collection continued for 6 minutes while the subject began active recovery by walking on the 
treadmill at a pace of 2.5 mph for 3 minutes then 2.0 mph for 3 minutes. 
Blood Pressure 
 Prior to the GEST, resting BP was obtained after the subject sat upright with their back 
and arms supported for 5 minutes. BP was measured manually in the right arm positioned at 
heart level by auscultation using a mercury sphygmomanometer (Trimline™, PyMaH Corp., 
Somerville, NJ, USA), a Trimline BP cuff (Omni Kuff®, Latex Free, Universally connection 
BALANCED® design, Trimline Medical Products, Somerville, NJ, USA) and a Cardiology 
stethoscope (3M™ Litman® Lightweight II SE, St. Paul, MN, USA). Exercising BP was 
recorded every 3 minutes and was measured at heart level with the subject’s arm relaxed and not 
grasping the handrails. Peak SBP was confirmed as the greatest BP recorded 1 minute prior to 
the conclusion of the GEST or immediately post-exercise (within 30 second of ceasing exercise) 
if peak SBP could not be attained at 1 minute prior to the conclusion of the GEST. A trained 
member of the study personnel measured SBP in the right arm by auscultation. If multiple BP 
measurements were recorded within the 1 minute prior and immediately post-exercise then the 
last measurement taken was used as the peak SBP. 
Data Administration 
 Data collected during STOMP was compiled in an online master database, which was 
maintained by the study coordinator, at Hartford Hospital, Hartford, CT. Investigators from 
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Hartford Hospital, the University of Connecticut and the University of Massachusetts, Amherst 
manually entered STOMP data into the online database. Access to the database was secured 
using confidential usernames and passwords and was limited to study personnel only.   
Statistical Analyses 
 The statistical approaches used addresed each of the following specific aims of the study: 
 Specific aim 1: To examine the association of VitD on resting BP. 
 Specific aim 2: To investigate the relationship between VitD and the peak SBP response 
to a GEST. 
 Descriptive statistics (mean  SEM) were calculated on all study variables for the total 
sample and by VitD status. Pearson product-moment correlation coefficients tested the 
relationship among resting SBP, DBP, MAP, the peak SBP achieved on the GEST, and VitD 
prior to randomization. Multivariable regression analyses were used to test the influence of VitD 
on resting SBP, DBP, MAP and the peak SBP achieved on the GEST. Analysis of covariance 
(ANCOVA) was then used to test the strength of the relationship between BP and VitD status 
with gender, BP medication, and VitD supplementation as fixed factors and age, BMI, and VO2 
peak as covariates. The dependent variables for the analyses were: resting SBP, DBP, MAP and 
peak SBP. The independent variable was VitD status. VitD status was determined as being above 
or below the median VitD level for the sample for purposes of statistical analyses. A Chi-square 
was used to test the relationship between subjects who on VitD supplementation and those on BP 
medication. 
 All statistical analyses were performed with the Statistical Package for the Social 
Sciences (SPSS) Base 19.0 for Macintosh (SPSS Inc, Chicago, IL) and p< 0.05 was used as the 
threshold for significance.  
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Chapter 4 – Results 
Descriptive Characteristics 
Sample Characteristics  
Descriptive characteristics are shown in Table 1. The sample for this sub-study (n=417) 
consisted of healthy, overweight, middle-aged men (n=203, 48.6%) and women (n=214, 51.3%) 
with optimal BP and poor physical fitness for individuals of their age [117]. Resting SBP 
(p=0.01), DBP (p=0.05), and MAP (p=0.01) were higher among men compared to women (Table 
2). The peak SBP response to a GEST (p<0.001) was also higher among men than women (Table 
3). Men had a greater BMI (p<0.001) and VO2 peak than the women (p<0.001). 
The sample as a whole had sufficient levels of VitD (Table 1), with women having higher 
levels than men (37.9 ± 15.1 ng/ml vs. 34.1 ± 11.2 ng/ml) (p=0.004) [8, 9]. However, 51.7% of 
the men and 44.9% of the women had VitD levels below the median of 34 ng/ml. Men in the 
VitD group below the median had a VitD level that was 17.7 ± 1.0 ng/ml lower than the men 
above the median (p<0.001). Women in the VitD group below the median had a VitD level 22.0 
± 1.4 ng/ml lower than the women above the median (p<0.001). Men in the VitD group below 
the median had a slightly lower VitD by 0.27 ± 0.8 ng/ml than the women in this VitD group 
(p>0.05). Men above the median had a VitD level 4.5 ± 1.5 ng/ml (p=0.003) lower than the 
women above the median. Appendix B contains scatterplots of VitD levels among the total 
sample and by gender. 
Subjects in the VitD group below the median had a lower VO2 peak [33.4 ± 9.7 vs. 34.3 ± 
9.7 (ml·kg-1·min-1)] and slightly higher BMI (26.8 ± 4.9 vs. 26 ± 4.8 kg/m2) and were younger 
in age (43.3 ± 14.7 yr. vs. 44.9 ± 17.3 yr.) compared to subjects with VitD above the median. 
Men in the VitD group below the median had a lower VO2 peak by 1.4 ± 1.3 mL/(kg·min), and 
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slightly higher BMI by 0.62 ± 0.6 kg·m-2 compared to the men above the median, however, 
neither difference was significant. Women in the VitD group below the median had lower VO2 
peak by 1.6 ± 1.2 mL/(kg·min), and a slightly higher BMI by 0.77 ± 0.6 kg·m-2 compared to the 
women above the median, however neither difference was significant. Men in the VitD group 
below the median had a higher VO2 peak by 8.5 ± 1.2 mL/(kg·min) (p<0.001), and BMI by 1.8 ± 
0.6 kg·m-2 (p=0.006) compared to the women below the median VitD. Men in the VitD group 
above the median had a higher VO2 peak by 1.4 ± 1.3 mL/(kg·min), and higher BMI by 0.62 ± 
0.6 kg·m-2 compared to the women above the median VitD, however neither difference was 
significant.  
VitD supplementation was taken by 24.1% of men and 32.2% of women. Among 
individuals who took VitD supplementation 53% of men and 59% of women have VitD levels 
above the median. Pearson’s Chi-squared revealed no association between VitD supplementation 
and VitD status among individuals in this sample. Of the total sample, 4.9% of the men and 4.2% 
of the women were taking antihypertensive medications. Among those taking antihypertensive 
medication, 77% of women and 50% of men were above the median. Of the individuals not 
taking antihypertensive medication 54% of women and 47% of men were above the median. 
Seasonal influence on VitD levels was significant in univariate models, however when 
controlling for age, sex and BMI, seasonal was not significant (p>0.05). This finding is 
consistent with those of Grimaldi et al. (2012) who found vitamin D was positively associated 
with isometric and isokinetic arm and leg strength measurements in univariate models. However, 
when including additional covariates such as SBP, DBP, BMI, V02max in multivariate analysis 
VitD did not have a direct impact on isometric leg strength [118].  
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Vitamin D and Resting Blood Pressure 
Table 2 contains resting BP by the median VitD level for the sample as a whole and by 
sex. Among the total sample, SBP (4.7 ± 12.2 mmHg, p<0.001), DBP (1.9 ± 8.7 mmHg, 
p=0.029) and MAP (2.8 ± 8.4 mmHg, p<0.001) were higher among those with VitD levels above 
the median compared to those below the median. Men with VitD below the median had a lower 
SBP by 5.9 ± 12.6 mmHg (p<0.001), DBP by 3.2 ± 9.8 mmHg (p=0.04), and MAP by 4.1 ± 9.9 
mmHg (p<0.001) than the men above the median VitD. Women with VitD below the median had 
a SBP 4.2 ± 13.8 mmHg (p=0.003) lower than the women above the median. Within the VitD 
group below the median men had a higher SBP by 5.1 ± 1.7 mmHg (p=0.004) and MAP by 2.6 ± 
1.3 mmHg (p=0.04) than the women below the median. Men above the median had a higher SBP 
by 6.7 mmHg, (p=0.003), DBP by 3.8 mmHg, (p=0.007) and MAP by 4.7 mmHg, (p=0.001) 
when compared to the women above the median.  
Vitamin D and the Peak SBP Response to a GEST 
Table 3 contains the peak SBP response to a GEST by median VitD level for the sample 
as a whole and by sex. Among the total sample, subjects with VitD levels below the median had 
a peak SBP that was 6.3 ± 21.3 mmHg lower than those above the median (p=0.04). Men below 
the VitD median had a peak SBP that was 8.4 ± 21.3 mmHg lower than those above the median 
(p=0.04). Similarly, women with a VitD below the median tended to have a peak SBP that was 
4.4 ± 19.4 mmHg lower than women above the median, however, this result did not achieve 
statistical significance (p >0.05). Men above the median had a peak SBP that was 18.8 ± 2.8 
mmHg higher than women above the median (p<0.001). Men below the median had a peak SBP 
14.8 ± 2.7 mmHg higher than women below the median (p<0.001). 
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Correlates of Resting Blood Pressure and the Peak Systolic Blood Pressure Response to a 
GEST 
 The models that emerged from the multivariable regression of correlates of resting BP 
and the peak SBP response to a GEST are shown in Table 4. VitD (4.0%, p=0.000), age (5.2%, 
p=0.000), sex (4.0%, p=0.000), and BMI (6.4%, p=0.000) explained 17.8% of the variability in 
resting SBP. VitD (1.0%, p=0.04, age (2.7%, p=0.001), sex (1.0%, p=0.045), and BMI (5.9%, 
p=0.000) explained 10.9% of the variability in resting DBP. VitD (2.5%, p=0.001), age (4.4%, 
p=0.000), sex (2.4%, p=0.002), and BMI (7.4%, p=0.000) explained 16.0% of the variability in 
resting MAP. VitD (1.4%, p=0.016), age (2.5%, p=0.001), sex (10.0%, p=0.000), and BMI 
(3.0%, p=0.001) explained 15.8% of the variability in peak SBP response to a GEST. 
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Table 1. Subject Characteristics (Mean ± SEM) among total sample and by sex and vitamin D level  
 
Variable Total Sample Vitamin D < 34 ng/ml Vitamin D ≥ 34 ng/ml 
  (N=417) (N=203) (N=214) 
  
Men (N=105) Women (N=96) Men (N=98) Women (N=118) 
Age (yr) 44.1 ± 0.8 42 ± 1.5 44.6 ± 1.4 45.2 ± 1.7 44.7 ± 1.7 
BMI (kg·m-2) 26.4 ± 0.2 †† 27.7 ± 0.5 25.9 ± 0.5 † 27.1 ± 0.4 25.1 ± 0.5 † 
Vitamin D 36.1 ± 0.7 †† 25.5 ± 0.5** 25.8 ± 0.6** 43.3 ± 0.8** 47.8 ± 1.2 †** 
VO2 peak  (ml·kg
-1·min-1) 33.9 ± 0.5 †† 37.5 ± 0.9 28.9 ± 0.9†† 39.0 ± 0.9 30.6 ± 0.8 †† 
Blood Pressure Medication Use  19 5 2 5 7 
Vitamin D Supplementation Use 118 23 28 26 41 
BMI, Body Mass Index; VO2peak , Peak Oxygen Consumption 
† p<0.05, †† p<0.001 Men vs. Women 
* p<0.05, **p<0.001 Vitamin D, <34 ng/mL vs. ≥34 ng/mL 
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Table 2. Average adjusted resting blood pressure (Mean ± SEM) among the total sample and by median vitamin D level and sex. 
Resting Blood 
Pressure (mmHg) 
Total Sample 
       Vitamin D 
       <34 ng/mL 
Vitamin D 
≥34 ng/mL 
Total n=417        n=203 n=214 
          SBP 118.9 ± 0.6        116.6 ± 0.9 121.3 ± 0.9** 
          DBP 75.3 ± 0.5        74.3 ± 0.6 76.2 ± 0.6* 
          MAP 89.9 ± 0.5        88.4 ± 0.6 91.2 ± 0.6** 
 
   
Men n=203        n=105 n=98 
          SBP 117.2 ± 0.8        119.0 ± 1.2 124.9 ± 1.2** 
          DBP 76.5 ± 0.6        75.1 ± 0.9 78.3 ± 0.9* 
          MAP 91.6 ± 0.7        89.7 ± 0.9 93.8 ± 0.9** 
    
Women n=214        n=96 n=118 
          SBP 113.0 ±0.8 ††        114.0 ± 1.2 † 118.2 ± 1.1 †** 
          DBP 74.3 ± 0.6       73.6 ± 0.9 74.5 ± 0.9 † 
          MAP 88.6 ± 0.6        87.1 ± 0.9 89.1 ± 0.9 
Adjusted for age, body mass index, sex, V02, and BP medication use 
BP, Blood Pressure; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; MAP, mean arterial pressure; BMI, body mass index 
 † p<0.05, †† p<0.001 Men vs. Women 
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 Table 3. Average adjusted peak systolic blood pressure (Mean ± SEM) response to a GEST among the total sample and by 
the median vitamin D level and sex. 
    
Peak Systolic Blood Total Sample Vitamin D Vitamin D 
Pressure (mmHg)   <34 ng/mL ≥34 ng/mL 
    
 
n=277 n=139 n=138 
Total 169.4 ± 1.1 166.6 ± 1.6 172.6 ± 1.6* 
    
 
n=138 n=74 n=64 
Men 177.1 ± 1.6 173.6 ± 2.3 182.0 ± 2.5* 
    
 
n=139 n=65 n=74 
Women 161.7 ± 1.6†† 158.8 ± 2.0 †† 163.2 ± 1.9 †† 
Adjusted for age, body mass index, sex, V02, and BP medications 
BP, Blood Pressure; SBP, Systolic Blood Pressure; GEST, Graded Exercise Stress Test 
 † p<0.05, †† p<0.001 Men vs.Women 
  * p<0.05, Vitamin D, <34 ng/mL vs. ≥34 ng/mL 
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Table 4. Multivariable regression of correlates of resting BP and the peak SBP response to a GEST 
  
Dependent variable Predictors β t Partial r r2 P 
Resting systolic blood pressure 
 
          
 
VitD 0.186 4.153 0.2 0.178 0.000 
 
Age 0.176 4.74 0.227 
 
0.000 
 
Sex -5.033 -4.015 -0.199 
 
0.000 
 
BMI 0.677 4.153 0.254 
 
0.000 
Resting diastolic blood pressure 
      
 
VitD 0.07 2.065 0.101 0.109 0.04 
 
Age 0.095 3.38 0.164 
 
0.001 
 
Sex -1.858 -2.008 -0.098 
 
0.045 
 
BMI 0.487 5.068 0.242 
 
0.000 
Resting mean arterial blood pressure 
      
 
VitD 0.109 3.217 0.157 0.16 0.001 
 
Age 0.122 4.356 0.21 
 
0.000 
 
Sex -2.916 -3.163 -0.154 
 
0.002 
 
BMI 0.55 5.744 0.272 
 
0.000 
Peak systolic blood pressure 
 
     
 
VitD 0.172 2.424 0.119 0.158 0.016 
 
Age 0.19 3.24 0.158 
 
0.001 
 
Sex -12.78 -6.599 -0.309 
 
0.000 
 
BMI 0.668 3.317 0.161 
 
0.001 
VitD, vitamin D; BMI, body mass index 
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Chapter 5 - Discussion 
Hypertension is a highly prevalent risk factor for CVD-related death [3]. More than a 
quarter of all adults ≥ 20 yr are living with hypertension and nearly a fifth of all adults ≥ 20 yr 
have elevated BP but remain unaware of it [2]. Even among adults (50 yr) with normal BP, there 
is a 90% risk of developing hypertension during their lifetimes [4]. Thus it is important to further 
our understanding of hypertension, what precipitates its incidence, and how it can be prevented. 
One controllable variable that may influence BP is serum VitD levels. Accumulating 
evidence indicates the risk of hypertension is associated with VitD deficiency [5-7]. For 
example, the prevalence of hypertension was found to be 30% higher among people in the lowest 
quartile of serum VitD levels relative to those in the highest quartile.[10] Additional studies have 
supported these claims, reporting that lower serum VitD levels associate with elevated resting BP 
[22-25]. However, other authors have reported conflicting views. For example, several studies 
found VitD to have no effect on resting BP [13, 26-29] and still other studies found elevated 
VitD levels to correspond to increases in resting BP [14, 30-32].  
We attempted to explore these discrepant findings in a sample of 417 healthy men and 
women who neither have VitD deficiency nor hypertension. Patients across the lifespan, age 20 – 
81 yr, were divided by the median level of serum VitD (34 ng/ml) and the relationship between 
serum VitD and BP was evaluated. BP was measured both by resting evaluations and by peak 
SBP response to a GEST, as elevations in peak BP, particularly SBP, during a GEST can predict 
future onset of hypertension [33-39]. Owing to trends in the literature, we had anticipated finding 
individuals with the lowest serum VitD to manifest the highest resting BP as well as the highest 
peak SBP during a GEST. The major findings were that resting BP was significantly higher 
among individuals with VitD levels above the median compared to those below the median. 
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Among the subjects who achieved a peak SBP response to a GEST, a similar result was found: 
we recorded higher peak SBP values for subjects whose VitD levels were above the median 
(p=0.04).  
Gender differences were also found. Overall, men displayed a higher resting SBP 
(p=0.01), DBP (p=0.05), and MAP (p=0.01) than women. Peak SBP during the GEST was also 
higher among men than women (p<0.001). Men with VitD levels below the median had lower 
resting SBP and DBP than those with VitD levels above the median. Similarly, women with 
VitD levels below the median had a lower resting SBP when compared to women above the 
median (p=0.003).  
These findings are important because, while the previous literature was conflicted, the 
majority of the studies reported either no association between BP and VitD or the relationship to 
be inverse, whereby lower VitD levels correspond to higher BP [20, 67, 68, 75]. Three recent 
meta-analyses have analyzed the relationship between VitD levels and BP. In 2009, Witham and 
colleagues [20] investigated the effect of VitD supplementation on BP among men and women 
with hypertension, finding VitD to have a very weak, non-significant BP-lowering effect. Of 
note, all subjects in this meta-analysis had confirmed hypertension. In 2010, Burgaz and 
colleagues found VitD levels to be inversely associated with BP. However, the primary aim for 
the majority of the studies included in the Burgaz analysis was to determine the association 
between VitD and the metabolic syndrome and therefore included a cohort that would have been 
otherwise excluded from the present study due to health requirements. A second meta-analysis 
conducted by Elamin and colleagues. (2011) found no association between VitD status and BP 
among 1,518 individuals across 14 studies. However, this work included patients with chronic 
kidney disease, Type 2 diabetes mellitus, and the metabolic syndrome. Therefore, the findings 
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from both meta-analyses cannot be readily generalized to our subject population, which 
consisted of only healthy adults.  
Moreover, many of the studies examining the association between VitD and BP have 
relatively low quality consequent of poor methodology. For example, it is not uncommon for 
studies to include self-reported BP measurements status [11,107,109] or estimate VitD status by 
scrutinizing dietary logs rather than collecting blood samples [109]. Studies with such 
methodological limitations are routinely included in the systematic reviews and meta-analyses 
examining the relationship between VitD and BP, and thus the conclusions of these reports may 
not be trustworthy. In addition to our subjects being healthy and our methods being sound, 
another explanation for the discrepant findings is the average VitD levels in our population. Most 
of the existing research has examined patients with VitD deficiency or insufficiency and their 
risk of hypertension. Thus the tested cohort typically has a mean VitD level <25 ng/mL. By 
comparison, the subjects in this study had a median VitD level of 34 ng/mL, so the question was 
not whether deficiency precipitates changes in BP, but if fluctuations within a normal range can 
also elicit change. 
A possible physiological explanation for the elevated BP among people with increased 
VitD levels relates to its primary role: regulation of the intestinal absorption of calcium and 
phosphate. An excess of circulating VitD may disrupt mineral levels within the vasculature and 
lead to increased mineralization (e.g., calcium deposits) within the vessel walls. In turn, this can 
lead to vascular hardening and inflammation [42]. Furthermore, when calcium and phosphate 
levels build up, it can induce the breakdown of elastin, resulting in the deterioration of the 
arterial walls, reducing reactivity and elasticity, and ultimately increasing BP [42]. It is likely 
that VitD can stimulate vascular calcification not just during deficiency, but also during excess 
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(>30 ng/ml)  [43].  One area that particularly warrants further investigation is in the gender roles. 
In our study, men displayed a higher resting SBP, DBP, and MAP than women as well as a 
higher peak SBP during the GEST. In the literature, the relative risk for developing hypertension  
among people deficient in VitD was higher in men [11] and there may be more to this 
relationship. Muray and colleagues (2003) found BP to be higher in men with elevated VitD 
levels, but no association between VitD and resting BP among women [14]. Further exploration 
into the effect of gender on VitD’s relationship with BP may be revealing. 
Limitations and Strengths 
A primary delimitation posing a threat to the external validity is that STOMP was not 
designed to address the primary aims associated with this sub-study. The original objectives of 
the STOMP study did not include resting BP or the peak SBP response to a GEST as primary 
outcomes. Therefore, the peak SBP response to a GEST was obtained in 277 participants out of a 
total sample size of 417 individuals.  A potential threat to internal validity exists among the 
consistency and reliability of data collection and reporting methods and procedures across the 3 
data collection sites. Discordant interpretations during data collection and entry at the different 
sites are a potential weakness. To minimize this threat a standardized database, testing protocol 
and equipment were used at each site. Additionally, investigators responsible for data collection 
at each site participated in mandatory monthly meetings to discuss study progress and ensure 
investigators at each site were accurately following the study protocol, limiting the opportunity 
for bias during data collection and entry [40]. 
A third limitation is the possibility that the relationship between VitD and blood pressure 
was offset by the use of antihypertensive medications, as subjects were enrolled in the study as 
long as their BP was controlled (140/90 mmHg), and they had not newly initiated treatment. 
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Antihypertensive medications may have offset the potential influence of VitD levels in some 
patients. There are several strengths to the STOMP study including the large sample of healthy 
men and women (n= 417) with a wide age range (20 – 81 yr.) The wide age range used in this 
STOMP sub-study allows for the findings to be generalized to a larger group of people.   
An additional limitation is that dietary intake was not recorded or monitored for duration 
of the STOMP study. A dietary record of the quantity and percentage of macro and 
micronutrients consumed by the sample, such as calcium, may be an important covariate when 
examining the association between VitD and BP. VitD is significantly more effective in reducing 
SBP when supplemented with the proper amount of calcium.  If an individual is calcium 
deficient then VitD alone is less likely to have a BP altering effect [41,46]. Additionally, sodium 
chloride (table salt) which has no association to VitD levels and a strong association to BP could 
have been an important covariate if recorded [86]. 
Lastly, the median VitD level among the sample was 34 ng/ml, which greatly exceeds the 
Vit D levels examined in the majority of previous literature. Therefore the findings put forward 
from this sub-study highlight a unique sample not well represented in previous studies examining 
the relationship between BP and VitD. 
Conclusion 
We found VitD levels to positively associate with BP among 417 healthy men and 
women across the lifespan who had a resting MAP of 90mmHg and median VitD of 34 ng/mL. 
BP was measured both at rest and during a maximal GEST, and the positive association with 
VitD levels was found in both scenarios. These results are atypical and would benefit from 
additional research. This is the first study to examine the association between VitD levels and the 
peak SBP response to a graded GEST and therefore offers preliminary data in that domain.
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Abbreviations: SBP, systolic blood pressure; yr, years; BMI, body mass index; ng/ml, nanograms per milliliter; HTN, hypertension; NA, not available 
 
 
 
 
 
Appendix A. 
 
Table 1. 
Cross-sectional studies reporting an inverse association between vitamin D and blood pressure 
 
Year     Author N               Population 
Mean Vit D 
(ng/ml) 
 Mean 
SBP 
  Mean 
  Age 
Mean 
BMI 
        
2011 Deo et al. 2312 Healthy men and women 21.8 139 74 27.3 
2011 Burgaz et al. 833 Healthy Caucasian men 27.7 140 71.8 25.8 
2010 Kim et al. 324 Healthy men and women  18.3 138 65.8 23.7 
2010 Zhao et al. 7228 Healthy men and women  23.2 120 47.4 28.7 
2009 Gannage-Yared et al. 381 Healthy men and women 31 110 23.9 23.9 
2009 Schmitz et al. 1334 Hispanic and African American men and women  14.8 NA 38.5 NA 
2008 Rueda et al. 298 Obese men and women  19.1 NA 42.9 46.7 
1997 Kristal-Boneh et al. 100 Male industrial employees  25.3 121 41.9 26.3 
1994 Duprez et al. 25 Individuals with HTN  17.6 164 44.1 NA 
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Table 2. 
Cross-section studies reporting no association between vitamin D and blood pressure 
 
Year     Author N        Population 
Mean Vit D  
(ng/ml) 
Mean  
SBP 
Mean  
Age (yr) 
Mean  
BMI 
        
2012     Li et al. 1420 Chinese men and women 23 124.3 47 23.2 
2011     Scragg et al. 119 Healthy men 17 134 57 33 
2011     Griffin et al. 559 Healthy females 23.5 119 37.7 26.8 
2011     Chan et al. 939 Chinese males  31.2 142 72.8 23 
2010     Jorde et al. 2385 Healthy men and women 21.5 139 56.2 26.2 
1995    Scragg et al. 191 Non-medicated individuals with HTN  13.2 NA 70 NA 
1995    Lind et al. 34 Non-medicated men  36.1 143 63 NA 
A    Abbreviations: SBP, systolic blood pressure; yr, years; BMI, body mass index; ng/ml, nanograms per milliliter; HTN, hypertension; NA, not available 
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Table 3. 
Cross-section studies reporting a positive association between vitamin D and blood pressure 
 
Year Author N        Population 
Mean Vit D 
(ng/ml) 
Mean  
SBP 
Mean  
Age (yr) 
Mean  
BMI 
        
2003 Muray et al. 590 Healthy men and women 22.8 122 36 24.7 
1988 Sowers et al. 373 Healthy women 24.3 128 NA NA 
Abbreviations: SBP, systolic blood pressure; yr, years; BMI, body mass index; ng/ml, nanograms per milliliter; HTN, hypertension; NA, not available 
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Appendix B. 
 
 Chart 1. 
 Vitamin D levels among the total sample 
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Chart 2. 
Vitamin D levels among men  
 
VitD, vitamin D; ng/ml, nanograms per millileter; yrs, years 
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Chart 3. 
Vitamin D levels among women 
 
VitD, vitamin D; ng/ml, nanograms per millileter; yrs, years 
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